| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Arisa Tsurue, Hideki Funahashi, Keiichi Tsurue, Masahiko Kawano, Yasushi Ishida, Yoji Hiran. A case study of the utilization of clozapine treatment for treatment-resistant schizophrenia associated with 22q11.2 deletion syndrome. Neuropsychopharmacology reports. 2023-03-17. PMID:36929244. |
a case study of the utilization of clozapine treatment for treatment-resistant schizophrenia associated with 22q11.2 deletion syndrome. |
2023-03-17 |
2023-08-14 |
human |
| C Okhuijsen-Pfeifer, M Z van der Horst, J J Luyk. [Towards personalized treatment with clozapine]. Tijdschrift voor psychiatrie. vol 65. issue 2. 2023-03-13. PMID:36912056. |
clozapine is the most effective treatment for people with treatment-resistant schizophrenia. |
2023-03-13 |
2023-08-14 |
Not clear |
| Solveig Sæther Jensen, Jakob Christensen, Biger Johnsen, Simon Hjerril. Ugeskrift for laeger. vol 185. issue 9. 2023-03-10. PMID:36896614. |
this case report presents a 28-year-old female with schizophrenia in clozapine treatment developing ncse twice after two different series of ect treatment. |
2023-03-10 |
2023-08-14 |
Not clear |
| Somdatta Saha, Javier González-Maes. The crosstalk between 5-HT Neuropharmacology. 2023-03-08. PMID:36889432. |
first generation or typical such as haloperidol and second generation or atypical such as clozapine and risperidone remain the current standard for schizophrenia treatment. |
2023-03-08 |
2023-08-14 |
Not clear |
| Fernando Facal, Javier Costa. Polygenic risk scores for schizophrenia and treatment resistance: New data, systematic review and meta-analysis. Schizophrenia research. vol 252. 2023-02-28. PMID:36657363. |
although treatment-resistant schizophrenia (trs) is an important and frequent problem with a specific treatment, clozapine, its biological determinants are poorly understood. |
2023-02-28 |
2024-03-16 |
Not clear |
| Jan P A M Bogers, Peter F J Schulte, Theo G Broekman, Lieuwe de Haa. Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia. Journal of clinical psychopharmacology. 2023-02-24. PMID:36825865. |
feasibility and effect of increasing clozapine plasma levels in long-stay patients with treatment-resistant schizophrenia. |
2023-02-24 |
2023-08-14 |
Not clear |
| Jan P A M Bogers, Peter F J Schulte, Theo G Broekman, Lieuwe de Haa. Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia. Journal of clinical psychopharmacology. 2023-02-24. PMID:36825865. |
it is unknown whether increasing the clozapine plasma level to 400, 750, or even 1000 ng/ml is a feasible and effective strategy in patients with treatment-resistant schizophrenia (trs). |
2023-02-24 |
2023-08-14 |
Not clear |
| Miriam Olivola, Vincenzo Arienti, Nicola Bassetti, Gianluca Giovanna, Natascia Brondin. Lurasidone Augmentation of Clozapine in Refractory Schizophrenia: A Case Series. Journal of clinical psychopharmacology. 2023-02-24. PMID:36825872. |
lurasidone augmentation of clozapine in refractory schizophrenia: a case series. |
2023-02-24 |
2023-08-14 |
Not clear |
| Miriam Olivola, Vincenzo Arienti, Nicola Bassetti, Gianluca Giovanna, Natascia Brondin. Lurasidone Augmentation of Clozapine in Refractory Schizophrenia: A Case Series. Journal of clinical psychopharmacology. 2023-02-24. PMID:36825872. |
clozapine represents the criterion standard therapy for patients with treatment-resistant schizophrenia. |
2023-02-24 |
2023-08-14 |
Not clear |
| Kathleen Hurley, Sinead O'Brien, Ciaran Halleran, Derina Byrne, Erin Foley, Jessica Cunningham, Fionnuala Hoctor, Laura J Sah. Metabolic Syndrome in Adults Receiving Clozapine; The Need for Pharmacist Support. Pharmacy (Basel, Switzerland). vol 11. issue 1. 2023-02-24. PMID:36827661. |
people who are diagnosed with treatment resistant schizophrenia (trs) are likely to have clozapine as a therapeutic management option. |
2023-02-24 |
2023-08-14 |
Not clear |
| Austin G Armstrong, Sheldon H Preskor. Thoughts on the Value of Case Series in the Literature: An Example Using the Article on Lurasidone Augmentation of Clozapine in Refractory Schizophrenia. Journal of clinical psychopharmacology. 2023-02-23. PMID:36821468. |
thoughts on the value of case series in the literature: an example using the article on lurasidone augmentation of clozapine in refractory schizophrenia. |
2023-02-23 |
2023-08-14 |
Not clear |
| Spyridon Siafis, Johannes Schneider-Thoma, Tasnim Hamza, Irene Bighelli, Shimeng Dong, Wulf-Peter Hansen, John M Davis, Georgia Salanti, Stefan Leuch. Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. BMJ open. vol 13. issue 2. 2023-02-22. PMID:36810167. |
efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. |
2023-02-22 |
2023-08-14 |
human |
| Spyridon Siafis, Johannes Schneider-Thoma, Tasnim Hamza, Irene Bighelli, Shimeng Dong, Wulf-Peter Hansen, John M Davis, Georgia Salanti, Stefan Leuch. Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. BMJ open. vol 13. issue 2. 2023-02-22. PMID:36810167. |
guidelines recommend clozapine for treatment-resistant schizophrenia. |
2023-02-22 |
2023-08-14 |
human |
| Caroline Fenton, Connie Kan. Clozapine is the approved option in treatment-resistant schizophrenia and requires careful management. Drugs & therapy perspectives : for rational drug selection and use. 2023-02-22. PMID:36811119. |
clozapine is the approved option in treatment-resistant schizophrenia and requires careful management. |
2023-02-22 |
2023-08-14 |
Not clear |
| Antonio F Pardiñas, Djenifer B Kappel, Milly Roberts, Francesca Tipple, Lisa M Shitomi-Jones, Adrian King, John Jansen, Marinka Helthuis, Michael J Owen, Michael C O'Donovan, James T R Walter. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. The lancet. Psychiatry. vol 10. issue 3. 2023-02-21. PMID:36804072. |
the antipsychotic, clozapine, is the only licensed drug against the treatment-resistant symptoms that affect 20-30% of people with schizophrenia. |
2023-02-21 |
2023-08-14 |
Not clear |
| Suzanne Reeves, Julie Bertrand, Stephen John Obee, Samora Hunter, Robert Howard, Robert James Flanaga. A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status. British journal of clinical pharmacology. 2023-02-16. PMID:36793249. |
guidance on clozapine dosing in treatment-resistant schizophrenia is based largely on data from white young adult males. |
2023-02-16 |
2023-08-14 |
Not clear |
| Robert James Flanagan, Samora Hunter, Stephen John Obee, Suzanne Reeve. Clozapine: Dose, Sex, Ethnicity, Smoking Habit, Age, Body Weight, and Plasma Clozapine and N-Desmethylclozapine (Norclozapine) Concentrations in Clinical Practice. Journal of clinical psychopharmacology. 2023-02-03. PMID:36735578. |
guidance on clozapine dosing in treatment refractory schizophrenia is based largely on data from young adult male white patients. |
2023-02-03 |
2023-08-14 |
Not clear |
| Yuto Masumo, Nobuhisa Kanahara, Masanobu Kogure, Fumiaki Yamasaki, Yusuke Nakata, Masaomi Iy. Dopamine supersensitivity psychosis and delay of clozapine treatment in patients with treatment-resistant schizophrenia. International clinical psychopharmacology. vol 38. issue 2. 2023-01-31. PMID:36719338. |
dopamine supersensitivity psychosis and delay of clozapine treatment in patients with treatment-resistant schizophrenia. |
2023-01-31 |
2023-08-14 |
Not clear |
| Yuto Masumo, Nobuhisa Kanahara, Masanobu Kogure, Fumiaki Yamasaki, Yusuke Nakata, Masaomi Iy. Dopamine supersensitivity psychosis and delay of clozapine treatment in patients with treatment-resistant schizophrenia. International clinical psychopharmacology. vol 38. issue 2. 2023-01-31. PMID:36719338. |
the present study retrospectively assessed dopamine supersensitivity psychosis (dsp) in addition to other measures such as age at disease onset and delay of clozapine introduction for a total of 47 treatment-resistant schizophrenia (trs) patients. |
2023-01-31 |
2023-08-14 |
Not clear |
| Srinivasan Tirupat. Ultra-Treatment-Resistant Schizophrenia and Clozapine Augmentation. Journal of clinical psychopharmacology. 2023-01-31. PMID:36719407. |
ultra-treatment-resistant schizophrenia and clozapine augmentation. |
2023-01-31 |
2023-08-14 |
Not clear |